Supplemental NDA to FDA submitted for Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis
“Today’s submission is an important step toward our goal of bringing the combination of selinexor plus ruxolitinib to patients with myelofibrosis who continue to face a significant unmet need,” said Reshma Rangwala, M.D., Ph.D., Chief Medical Officer and Head of Research of Karyopharm. “The SENTRY trial generated compelling and consistent results, including rapid, deep and sustained spleen responses across a broad range of patients, together with a promising overall survival signal and important evidence of disease modification. We believe the strength of these data underscores the potential of this novel combination to deliver meaningful long-term benefits and fundamentally change the treatment of patients with myelofibrosis.”
Share:
More News
Dr Jing He, Head of R&D China, AstraZeneca, said: “These positive data underscore the pivotal role of ORPATHYS® in intercepting MET-driven resistance early in the treatment journey. By combining the targeted precision of ORPATHYS® with backbone TAGRISSO®, SANOVO demonstrates a meaningful clinical advancement for treatment-naïve patients with MET overexpression and
“ADI-212 marks an important milestone in Adicet’s strategy to address the complexity of solid tumors and represents an important addition to our portfolio of allogeneic gamma delta 1 cell therapies and in vivo CAR T programs,” said Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio. “Designed as a single
“Any decision concerning clinical trials is made with utmost care, keeping patients as our highest priority,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “While this outcome is not what we had envisioned for mRNA as a monotherapy in colorectal cancer, it provides scientific insight into
“These results reinforce our confidence that Ziihera is the new HER2-targeted backbone therapy in first-line HER2+ advanced GEA, replacing trastuzumab and extending survival beyond the current standard of care,” said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals.